Brain

Hyperfine, Inc. to Host Analyst and Investor Education Webcast with Clinical and Brain Imaging Experts on June 25, 2024

- Led by Edmond Knopp, MD, VP of Medical Affairs - Welcoming three KOLs to discuss clinical developments in ultra-low-field…

6 days ago

Psirenity Health Adds Key Executive to its Experienced and Innovative Leadership Team

Oakville, Ontario--(Newsfile Corp. - June 3, 2024) - Psirenity Health is incredibly pleased to announce that Mr. Andrew Macdonald has…

7 days ago

CNS Pharmaceuticals Announces Reverse Stock Split

HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…

7 days ago

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024HOUSTON, TX, June 03, 2024 (GLOBE…

7 days ago

Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial

The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular…

7 days ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and…

1 week ago

ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System

Newly Launched Technology Will Be on Display at ASSFN in Nashville from June 1 - 4 ClearPoint Neuro Announces Full…

1 week ago

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon…

1 week ago